Last reviewed · How we verify
ISIS 416858
At a glance
| Generic name | ISIS 416858 |
|---|---|
| Also known as | IONIS-FXIRx, ISIS-FXI Rx, BAY2306001, IONIS-FXI Rx |
| Sponsor | Ionis Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis (PHASE2)
- A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis (PHASE2)
- Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ISIS 416858 CI brief — competitive landscape report
- ISIS 416858 updates RSS · CI watch RSS
- Ionis Pharmaceuticals, Inc. portfolio CI